NO994850D0 - Farmakologiske midler - Google Patents

Farmakologiske midler

Info

Publication number
NO994850D0
NO994850D0 NO994850A NO994850A NO994850D0 NO 994850 D0 NO994850 D0 NO 994850D0 NO 994850 A NO994850 A NO 994850A NO 994850 A NO994850 A NO 994850A NO 994850 D0 NO994850 D0 NO 994850D0
Authority
NO
Norway
Prior art keywords
pharmacological agents
pharmacological
agents
Prior art date
Application number
NO994850A
Other languages
English (en)
Norwegian (no)
Other versions
NO994850L (no
Inventor
David Bleakman
David R Helton
David Lodge
Smriti Iyengar
Paul L Ornstein
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of NO994850D0 publication Critical patent/NO994850D0/no
Publication of NO994850L publication Critical patent/NO994850L/no

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/472Non-condensed isoquinolines, e.g. papaverine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/472Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D217/00Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/26Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
NO994850A 1997-04-07 1999-10-05 Farmakologiske midler NO994850L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4279597P 1997-04-07 1997-04-07
PCT/US1998/006905 WO1998045270A1 (fr) 1997-04-07 1998-04-06 Agents a action pharmacologique

Publications (2)

Publication Number Publication Date
NO994850D0 true NO994850D0 (no) 1999-10-05
NO994850L NO994850L (no) 1999-10-05

Family

ID=21923795

Family Applications (1)

Application Number Title Priority Date Filing Date
NO994850A NO994850L (no) 1997-04-07 1999-10-05 Farmakologiske midler

Country Status (17)

Country Link
US (1) US6242462B1 (fr)
EP (1) EP0980358A4 (fr)
JP (1) JP2001521505A (fr)
KR (1) KR20010006075A (fr)
CN (1) CN1259126A (fr)
AU (1) AU734657B2 (fr)
BR (1) BR9809071A (fr)
CA (1) CA2285192A1 (fr)
EA (1) EA199900912A1 (fr)
HU (1) HUP0002030A3 (fr)
ID (1) ID23013A (fr)
IL (1) IL132086A0 (fr)
NO (1) NO994850L (fr)
NZ (1) NZ337827A (fr)
PL (1) PL336068A1 (fr)
TR (1) TR199902449T2 (fr)
WO (1) WO1998045270A1 (fr)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1200073T3 (da) 1999-07-06 2007-05-07 Lilly Co Eli Selektive iGluR5-receptorantagonister til behandling af migræne
AU5591900A (en) * 1999-07-06 2001-01-22 Eli Lilly And Company Diester prodrugs of a decahydroisoquinoline-3-carboxylic acid
EP1257545A1 (fr) 1999-12-22 2002-11-20 Eli Lilly And Company Antagonistes selectifs du recepteur iglur 5?
WO2002053139A2 (fr) * 2001-01-05 2002-07-11 Eli Lilly And Company Combinaison d'antagoniste de recepteur d'acide amine excitateur et d'agoniste 5-ht1f : methode de traitement de troubles neurologiques
AU2002227020A1 (en) 2001-01-05 2002-07-16 Eli Lilly And Company Pyrrolidinylmethyl- and piperidinyl substituted decahydroisoquinolines as excitatory amino acid receptor antagonists
MXPA03005982A (es) * 2001-01-05 2003-09-10 Lilly Co Eli Antagonistas de receptores de aminoacidos excitadores.
US7205313B2 (en) 2001-01-05 2007-04-17 Eli Lilly And Company Excitatory amino acid receptor antagonists
EP1351952A2 (fr) 2001-01-05 2003-10-15 Eli Lilly And Company Antagonistes de recepteur d'acide amine excitateur
US6924294B2 (en) 2001-01-05 2005-08-02 Eli Lilly And Company Excitatory amino acid receptor antagonists
EP1355640A1 (fr) * 2001-01-23 2003-10-29 Neurosearch A/S Utilisation d'antagonistes glur5 non competitifs et selectifs en tant que composes de modulation d'un recepteur de glutamate
PT1511741E (pt) 2002-04-26 2013-02-05 Lilly Co Eli Derivados éster de um ácido deca-hidroisoquinolino-3- carboxílico como analgésicos
US20050101597A1 (en) * 2003-07-10 2005-05-12 Pharmacia Corporation Compositions of a cyclooxygenase-2 selective inhibitior and a non-NMDA glutamate modulator for the treatment of central nervous system damage
JP4964593B2 (ja) * 2003-09-25 2012-07-04 セノメド バイオサイエンシーズ,エルエルシー 神経学的病状の治療用のテトラヒドロインドロン誘導体
US20050107439A1 (en) * 2003-11-10 2005-05-19 Helton David R. Composition and method for treating emesis
HUE032743T2 (en) 2006-11-22 2017-10-30 Clinical Res Ass Llc A method for treating Down syndrome, fragilis X syndrome and autism
CA2686816A1 (fr) 2007-01-16 2008-07-24 The Johns Hopkins University Utilisation de divers antagonistes de recepteur de glutamate pour retarder ou prevenir l'activite plaquettaire ou pour traiter ou prevenir une maladie ou un trouble thrombotique
WO2009062134A1 (fr) * 2007-11-09 2009-05-14 Cenomed Biosciences, Llc Traitement des troubles du stress post-traumatique avec des composés de tétrahydroindolone et d'arylpipérazine
US20090264443A1 (en) * 2008-04-18 2009-10-22 David Helton Treatment of organophosphate exposure with tetrahydroindolone arylpiperazine compounds
WO2011109398A2 (fr) 2010-03-02 2011-09-09 President And Fellows Of Harvard College Procédés et compositions pour le traitement du syndrome d'angelman et des troubles du spectre autistique
US20110294879A1 (en) 2010-05-28 2011-12-01 Xenoport, Inc. Method of treatment of fragile x syndrome, down's syndrome, autism and related disorders
US20120016021A1 (en) 2010-07-15 2012-01-19 Xenoport, Inc. Methods of treating fragile x syndrome, down's syndrome, autism and related disorders
KR101746944B1 (ko) * 2015-09-23 2017-06-14 주식회사 포스코 도장 선영성이 우수한 도금강판의 제조방법 및 이에 의해 제조된 도금강판

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5284957A (en) 1992-09-03 1994-02-08 Eli Lilly And Company Excitatory amino acid receptor antagonists
US5446051A (en) * 1994-05-31 1995-08-29 Eli Lilly And Company Aryl-spaced decahydroisoquinoline-3-carboxylic acids as excitatory amino acid receptor antagonists
EP0809624B1 (fr) * 1995-02-15 2001-08-29 Bearsden Bio, Inc. Modulateurs a base d'aminoacides alkylcarboxy du recepteur de kanaite

Also Published As

Publication number Publication date
KR20010006075A (ko) 2001-01-15
HUP0002030A2 (hu) 2001-04-28
TR199902449T2 (xx) 2000-07-21
EA199900912A1 (ru) 2000-04-24
WO1998045270A1 (fr) 1998-10-15
PL336068A1 (en) 2000-06-05
AU6955598A (en) 1998-10-30
CN1259126A (zh) 2000-07-05
CA2285192A1 (fr) 1998-10-15
NZ337827A (en) 2000-12-22
ID23013A (id) 1999-12-30
HUP0002030A3 (en) 2002-01-28
EP0980358A4 (fr) 2001-02-07
IL132086A0 (en) 2001-03-19
NO994850L (no) 1999-10-05
BR9809071A (pt) 2000-08-01
EP0980358A1 (fr) 2000-02-23
AU734657B2 (en) 2001-06-21
JP2001521505A (ja) 2001-11-06
US6242462B1 (en) 2001-06-05

Similar Documents

Publication Publication Date Title
DE69831181D1 (de) Positionsbestimmung
ATA93198A (de) Fluoxetinpellets
NO994850D0 (no) Farmakologiske midler
ATA111897A (de) Kimme
ATE236897T1 (de) 3-benzylpiperidine
ATA112597A (de) Snowboard - bindung
ID20897A (id) Susunan penutup-rapat
FI972138A0 (fi) Returtraog i bestrykningsanordning
FI971344A0 (fi) En vattenavlaegsningsanordning foer en former
ATA86797A (de) Verschleissschuh
DE69708044D1 (de) Konstruktionsteil
ATA46498A (de) Kunststoffgleitbahn
BR9701194A (pt) Hidrociclo
FI972751A (fi) Ääntä hajottava soladiffusorirakenne
FI971698A0 (fi) Klingstyrenhet i en cirkelsaog
FI972640A0 (fi) Gapformare i en pappersmaskin/kartongmaskin
BR9701099A (pt) Acertrol i
FI972997A0 (fi) Anordning i en sugsamlarvagn
FI974635A0 (fi) I vaermebatteri integrerbar ventilkonstruktion
FI972891A0 (fi) I en vaeggkonstruktion infaellbart faerdigt elkanalnaet
FI971651A0 (fi) Spaormaskin i en elmaskin
FI971123A0 (fi) Foervarings- och transportredskap i synnerhet foer pappersprodukter
FI974354A0 (fi) Kvaevereducering i avloppsvatten
FI974373A0 (fi) Avgasutlopp i utombordsmotorer
SE9703419D0 (sv) Arrangemang

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application